IONIS insider exercises 10,200 options, sells shares under 10b5‑1
Rhea-AI Filing Summary
Insider transactions by Patrick R. O'Neil, EVP, CLO & General Counsel at Ionis Pharmaceuticals (IONS). On 10/06/2025 the reporting person exercised 10,200 non‑qualified stock options with an exercise price of $52.87 and immediately sold those shares under a Rule 10b5‑1 plan. The Form 4 reports two separate block sales that day: 10,200 shares sold at a weighted average price of $69.8872 and 3,241 shares sold at a weighted average price of $69.2651, reflecting multiple executions within disclosed price ranges.
Following these transactions the reporting person’s beneficial ownership of common stock declined from 67,330 shares to 53,889, and the number of options/derivative securities held after the activity is reported as 17,000 exercisable into common stock. The sales were made pursuant to a 10b5‑1 trading plan adopted on 05/02/2025, and the filer offers to provide transaction‑level price details on request.
Positive
- Sales executed under a Rule 10b5‑1 plan, indicating prearranged compliance with insider trading rules
- Options exercised and sold at prices above the exercise price (exercise $52.87 vs sales near $69.9), indicating realized option value
Negative
- Reported direct common stock ownership declined from 67,330 to 53,889 shares after the transactions
- Substantial share sales the same day as option exercise reduced insider ownership concentration, which may decrease insider stake alignment
Insights
TL;DR: Insider exercised options at $52.87 and sold shares under a 10b5‑1 plan, reducing holdings to 53,889 shares.
Exercising 10,200 options at an exercise price of $52.87 then selling those shares at weighted average prices near $69.9 indicates the reporting person monetized stock‑option value while complying with a prearranged trading plan. The Form 4 discloses two weighted‑average sale prices and notes the 10b5‑1 plan adoption date of 05/02/2025.
The main dependencies are the accuracy of the weighted‑average prices and the 10b5‑1 plan terms; the filer commits to provide per‑trade price details on request. Investors should note the decline in direct common stock from 67,330 to 53,889 shares and the remaining 17,000 options outstanding; monitor future Form 4s for additional option exercises or plan‑based sales.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (right to buy) | 10,200 | $0.00 | -- |
| Exercise | Common Stock | 10,200 | $52.87 | $539K |
| Sale | Common Stock | 10,200 | $69.8872 | $713K |
| Sale | Common Stock | 3,241 | $69.2651 | $224K |
Footnotes (1)
- Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 2, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.70 to $70.075 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.1912 to $69.32 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
